Tonight listed on Nasdaq! Aktis Oncology (AKTS.US) IPO pricing at $18 per share.

Focus on developing targeted radiopharmaceuticals to treat solid tumors, clinical stage biotechnology company Aktis Oncology (AKTS.US) will debut on the Nasdaq tonight by issuing 17.7 million shares of stock priced at $18 per share (at the high end of the $16 to $18 offering price range), raising $318 million. The company initially planned to issue 11.8 million shares at the same offering price range, but expanded the offering size on Wednesday. Partner Eli Lilly (LLY.US) has indicated they will subscribe to $100 million worth of stock. After pricing, Aktis' fully diluted market value will reach $1 billion. Aktis Oncology is a clinical-stage oncology company focused on developing alpha particle radiopharmaceuticals for common solid tumors. Their pipeline includes: Ac-AKY-1189 targeting Nectin-4 expressing cancers, currently in a multi-center US phase 1b clinical trial with approximately 150 patients enrolled, preliminary results expected in the first quarter of 2027; and Ac-AKY-2519 targeting tumors expressing B7-H3, planned to submit an Investigational New Drug (IND) application in 2026. Additionally, the company manages multiple domestic and international isotope supply partnerships, an internally constructed cGMP facility expected to be operational in 2026, and collaborates with partners in the discovery phase to advance more mini-protein radioligand projects. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen serve as joint bookrunners for this transaction.